Lb Pharmaceuticals (LBRX) Non Operating Investment Income (2024 - 2025)
Lb Pharmaceuticals' (LBRX) quarterly Non Operating Investment Income came in at $119000.0 in Q1 2025, down 67.13% quarter-over-quarter from $362000.0 in Q4 2024.
Lb Pharmaceuticals (LBRX) Non Operating Investment Income (2024 - 2025) Analysis & Trends
Lb Pharmaceuticals' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $119000.0 for Q1 2025.
- On a quarterly basis, Non Operating Investment Income changed N/A year-over-year to $119000.0 in Q1 2025; TTM through Mar 2026 was $119000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $119000.0, down 87.54% from the prior year.
- Non Operating Investment Income fell to $119000.0 in Q1 2025 per LBRX's latest filing, from $362000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $503000.0 in Q3 2024 and bottomed at $119000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | - |
| 10 | Lb Pharmaceuticals | 973.07 Mn | 973.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 503,000.00 |
| Sep 30, 2024 | 503,000.00 |